Phase 4 N=36 ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
HIV/AIDS
Primary: Hair Antiretroviral Imaging — 156.4826656; 1092.130868; 0.501209; 3942.692396 Signal Abundance (au)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals With Self-Perceived Thinning Hair
Hair Thinning
Primary: Hair Shedding (1-2 Hairs Per Unit) — 21; 10 Participants
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
N/A N=30 Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Number of Patients With SALT50 — 1; 1 Participants
Phase 3 N=15 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
Alopecia
Primary: Hair Density Change After Three Treatments — 175.1 percentage of pre-treatment hair density
N/A N=63 Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
Male Pattern of Hair Loss, Androgenic Alopecia
Primary: Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12 — 5.0; 5.1; 5.1; 5.1 Score on a scale
N/A N=61 Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
Female Pattern Hair Loss, Androgenic Alopecia
Primary: Change From Baseline in Investigator's Rating of Global Photographs at Week 12 — 4.9; 4.9; 4.8; 5.0 Score on a scale
Phase 4 N=17 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
Kidney Failure, Chronic · Growth Hormone Deficiency
Primary: The Change in Amount of Insulin Like Growth Factor (IGF-I) Generated (Day 8-day 1) — 115; 129 mcg/L
Phase 3 N=42 Growth Hormone Therapy in Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Phase 1 N=28 Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
Chemotherapy-Induced Alopecia
Primary: Dose-limiting Toxicities (DLT) of Topical Compound 31543 — 0; 0; 0; 0 Participants
N/A N=35 Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece
Hair Removal
Primary: Hair Count — 54 percentage of hair clearance — p=<0.001
N/A N=189 The OPENS Trial: Offering Women PrEP (Aim 1)
Human Immunodeficiency Virus Transmission · Sexually Transmitted Diseases
Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51
N/A N=160 Modulated Light Therapy in Participants With Pattern Hair Loss
Androgenetic Alopecia
Primary: Mean Change in Terminal Hair Count From Baseline to 16 Weeks — -15.53; 14.26; 18.94; 5.22 Change in total hair counts
Phase 2 N=120 To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
Androgenic Alopecia
Primary: Scalp Hair Density — 1.46; 2.58; -4.10; 6.68 Change from baseline (No. of hairs/cm2)
Phase 2 N=15 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Alopecia Areata
Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants